All In MedTech

FDA Clearance Tracker · P190032-S029

FoundationOne Liquid CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 27, 2026

Approved

Time to decision

490 days

Received Jan 22, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P190032-S029
Device name
FoundationOne Liquid CDx
Applicant location
Boston, MA
Received
Jan 22, 2025
Decided
May 27, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190032

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval order to expand the intended use of FoundationOne Liquid CDx (F1LCDx) to include a companion diagnostic indication for the detection of HRR gene alterations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) in patients with metastatic castrate-resistant prostate cancer (mCRPC) who may benefit from treatment with TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide).

Source documents

Other decisions for Foundation Medicine, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.